Imatinib inhibits the renewal and tumorigenicity of CT-26 colon cancer cells after cytoreductive treatment with doxorubicin

• Autorzy: Przybyszewska M. , Miloszewska J. , Kotlarz A. , Swoboda P. , Pysniak K. , Szczepek W. , Kaczmarek L. , Markowicz S.
• Języki publikacji: EN

Abstrakty

EN

Słowa kluczowe

EN

colorectal cancer; cancer stem cell; receptor tyrosine kinase; cytoreductive drug; doxorubicin; imatinib; tumourigenicity

• Wydawca: -
• Czasopismo: Archivum Immunologiae et Therapiae Experimentalis
• Rocznik: 2017
• Tom: 65
• Numer: 1
• Opis fizyczny: p.51-67,fig.,ref.

Twórcy

autor

Przybyszewska M.

• Department of Immunology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland

autor

Miloszewska J.

• Department of Immunology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland

autor

Kotlarz A.

• Department of Immunology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland

autor

Swoboda P.

• Department of Immunology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland

autor

Pysniak K.

• Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland

autor

Szczepek W.

• Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland

autor

Kaczmarek L.

• Pharmaceutical Research Institute, Rydygiera 8, 01-793 Warsaw, Poland

autor

Markowicz S.

• Department of Immunology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland

Identyfikatory

DOI

10.1007/s00005-016-0391-0